Últimas noticias sobre Nvni Group (NASDAQ:NVNI) Bolsa

Nvni Group

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

AMPG

AVGR

BIPC

CHEK

CREV

FDSB

HSDT

KORE

LAES

LIND

NCRA

NEUE

RELI

SLGL

TIVC

TLRY

TOVX

Carbon Revolution lidera con un aumento del 62,4% en el premercado. ¿Qué otras acciones destacaron antes de la apertura?

Las acciones de Carbon Revolution (CREV) están subiendo un 62%; 20 acciones que se están moviendo en el premercado

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

OCEA

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

Nvni Group Ltd

Scotiabank analyst Divya Goyal maintains TELUS Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TIXT#NYSE">TIXT</a>) with a Sector Perform and lowers the price target from $5 to $3.

Price Target

Analyst Ratings

TIXT

Scotiabank Maintains Sector Perform on TELUS Intl, Lowers Price Target to $3

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Apollo Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARI#NYSE">ARI</a>) with a Outperform and raises the price target from $10 to $10.5.

Keefe, Bruyette & Woods Maintains Outperform on Apollo Comml Real Est, Raises Price Target to $10.5

Benchmark analyst Nathan Martin reiterates Alliance Res Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARLP#NASDAQ">ARLP</a>) with a Buy and maintains $29 price target.

Reiteration

ARLP

Benchmark Reiterates Buy on Alliance Res Partners, Maintains $29 Price Target

Shares of Cantor Equity Partners Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) have surged 139% to $31.36 over the past week following the announcement of a <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44996542/cantor-equity-partners-shares-nearly-double-whats-going-on">merger</a> with Bitcoin-focused startup Twenty One.
What To Know: The merger, which values the combined entity at $3.6 billion, would make it the third-largest public holder of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), behind only Strategy and Tether. Twenty One is backed by major players including Tether, SoftBank and Strike founder Jack Mallers, who will take the helm as CEO of the merged company.
Mallers is best known as the <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44282155/strike-ceo-jack-mallers-predicts-bitcoin-could-become-the-dominant-store-of-value">founder of Strike</a>, a prominent Bitcoin payments platform that played a key role in El Salvador's Bitcoin adoption. A vocal Bitcoin advocate, he has been instrumental in advancing Bitcoin-native financial infrastructure on a global scale.
Twenty One currently <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44975441/cantor-fitzgerald-backed-twenty-one-launches-strategy-rival-at-3-billion-valuation">holds 42,000 Bitcoin</a> and aims to increase that position further. It also raised $585 million to fund additional Bitcoin purchases and business operations. The company plans to focus on Bitcoin-native financial tools, capital markets products and media, highlighting innovative metrics like "Bitcoin Per Share."
Pending shareholder approval, the newly combined company will trade under the ticker symbol "XXI" on the Nasdaq, signaling a bold new chapter in institutional Bitcoin exposure.
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/04/45069781/trumps-first-100-days-what-he-delivered-where-he-fell-short-how-markets-reacted">Trump&#8217;s First 100 Days: What He Delivered, Where He Fell Short, How Markets Reacted</a>
<h2 class="wp-block-heading">How To Buy CEP Stock</h2>
By now you're likely curious about how to participate in the market for Cantor Equity Partners &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Cantor Equity Partners, which is trading at $32.55 as of publishing time, $100 would buy you 3.07 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CEP has a 52-week high of $39.29 and a 52-week low of $9.99.

$BTC

Cantor Equity (CEP) Stock Surges Over 130% On Bitcoin Merger with Twenty One: What's Going On?

Plug Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) shares are in the spotlight Tuesday after rallying 26% to start the week. Here&#8217;s a look at <a href="https://www.benzinga.com/news/earnings/25/04/45038400/plug-power-rallies-as-new-financing-cost-cuts-boost-confidence-in-turnaround-plan">what&#8217;s going on</a>.
What Happened: Plug Power shares raced higher on Monday after the company reported preliminary first-quarter results and announced it secured a credit facility of up to $525 million.
Plug said it signed a definitive agreement with Yorkville Advisors for a secured debt facility that includes the issuance of up to&nbsp;$525 million&nbsp;of secured debentures. The arrangement includes an initial&nbsp;$210 million&nbsp;tranche, which will be fully funded at the initial closing, along with additional tranches of up to&nbsp;$315 million.&nbsp;
Plug Power said it expects to report first-quarter revenue of approximately $130 million to $134 million. Analysts are anticipating first-quarter earnings of $131 million, per <a href="http://pro.benzinga.com">Benzinga Pro</a> estimates. 
The company noted that it expects net cash usage in the first quarter of approximately $142 million, compared to $268 million in the first quarter of 2024. 
&#8220;Plug anticipates additional near-term reductions to net cash usage driven by hydrogen plant ramp-ups, additional cost downs, and additional price increases,&#8221; the company said. 
Check This Out: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45066479/rare-bullish-signal-just-flashed-on-wall-street-will-it-power-sp-500-to-6000">Rare Bullish Signal Just Flashed On Wall Street: Will It Power S&amp;P 500 To 6,000?</a>
Plug reported that it had $296 million in unrestricted cash as of March 31. The company is due to report audited first-quarter results in early May. In the preliminary release, the company also provided guidance for the second quarter.
Plug expects second-quarter revenue to be in the range of $140 million to $180 million versus estimates of $143.35 million. 
&#8220;We&#8217;ve made the tough decisions and put the structure in place to deliver improved operating leverage and capital efficiency,&#8221; said Andy Marsh, CEO of Plug Power. 
&#8220;Between strengthening our balance sheet, scaling hydrogen production, and streamlining operations, we&#8217;ve taken the right steps to position Plug for long-term success in the hydrogen economy.&#8221;
PLUG Price Action: <a href="http://benzinga.com/quote/PLUG">Plug shares</a> raced higher on Monday following the announcements. The stock was pulling back Tuesday at last check, down 4.5% at 97 cents at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: T. Schneider/Shutterstock.

Earnings

Guidance

PLUG

Plug Power Stock Is Trending Tuesday: What's Going On?

Scotiabank analyst Divya Goyal maintains Globant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>) with a Sector Perform and lowers the price target from $170 to $140.

GLOB

Scotiabank Maintains Sector Perform on Globant, Lowers Price Target to $140

Scotiabank analyst Divya Goyal maintains CGI (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GIB#TSX">GIB</a>) with a Sector Outperform and lowers the price target from C$185 to C$175.

TSX:GIB

TSX:GIB/A

Scotiabank Maintains Sector Outperform on CGI, Lowers Price Target to C$175

On Tuesday, Pfizer Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) reported first-quarter 2025 adjusted EPS of 92 cents, compared to 82 cents a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus of 67 cents</a>.
Pfizer&#8217;s sales fell 8% year over year to $13.71 billion, slightly below the consensus of $13.95 billion. This reflects an operational decrease of $908 million, or 6%, as well as an unfavorable impact of foreign exchange of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b45061905/pfizer-reports-solid-first-quarter-2025-results-and-reaffirms-2025-guidance" rel="noreferrer noopener">$256 million, or 2%</a>.
The operational decrease was primarily driven by a decline in Paxlovid revenues, partially offset by growth from the Vyndaqel family, Comirnaty, and several other products across categories despite the unfavorable impact of higher manufacturer discounts resulting from the Inflation Reduction Act (IRA) Medicare Part D Redesign.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44790653/pfizer-discontinues-once-daily-weight-loss-pill-over-liver-injury-in-one-patient" rel="noreferrer noopener">Pfizer Discontinues Once-Daily Weight Loss Pill Over Liver Injury In One Patient</a>
Quarterly Comirnaty&nbsp;revenues of $565 million increased 62% operationally compared with the prior-year quarter. Paxlovid revenue fell 75% operationally to $491 million.
Vyndaqel family drugs generated&nbsp;<a target="_blank" href="https://s28.q4cdn.com/781576035/files/doc_financials/2025/q1/Q1-2025-PFE-Earnings-Release-FINAL.pdf" rel="noreferrer noopener">sales</a> of $1.49 billion, up 33%. Eliquis, a blood thinner drug, generated sales of $1.92 billion, down 4%.
Nurtec ODT/Vydura sales jumped 40% to $248 million. Prevnar family pneumococcal vaccine sales dipped 1% to $1.66 billion, and Abrysvo RSV vaccine sales slumped 6% to $131 million.
In April,&nbsp;the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44876132/us-advisory-panel-votes-to-expand-recommendation-for-pfizer-gsks-rsv-vaccines-for-older-adults-below-60-years" rel="noreferrer noopener">respiratory tract disease (LRTD)</a>
Guidance:&nbsp;Pfizer reaffirms 2025 revenues of $61 billion-$64 billion compared to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43463168/pfizer-q4-earnings-revenue-and-eps-beat-seagen-and-covid-19-products-show-strength-issues-strong-fy25-outlook" rel="noreferrer noopener">consensus of $62.93 billion</a>. The company anticipates adjusted EPS of $2.80-$3.00 compared to consensus of $2.96.
Pfizer <a target="_blank" href="https://s28.q4cdn.com/781576035/files/doc_financials/2025/q1/Q1-2025-Earnings-Conference-Call-Prepared-Remarks-FINAL.pdf" rel="noreferrer noopener">adds</a> the guidance does not include the potential impact of future changes in trade and tariff policies.
Cost-Cutting Initiatives: Pfizer said it plans to save an extra $1.2 billion through its ongoing cost-cutting efforts, aiming to reach that goal by the end of 2027.
The savings will mainly come from lower spending on selling, informational, and administrative expenses (SI&amp;A), thanks to more automation, use of AI, and simpler business processes.
To make these changes, Pfizer expects to spend around $1.6 billion through 2027, mostly on severance pay, tech upgrades, and implementation costs.
The company still plans to achieve $4.5 billion in savings by the end of 2025. With the new target, total program savings are expected to reach about $5.7 billion by 2027.
As part of the plan, Pfizer expects to save around $500 million by streamlining its R&amp;D operations by the end of 2026, which will be reinvested into new research. Pfizer expects to spend about $600 million to implement these R&amp;D changes.
Price Action:&nbsp;At the last check on Tuesday, PFE stock was up 3.41% to $23.84.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45069668/astrazeneca-q1-sales-and-earnings-rise-warns-china-import-tax-could-be-up-to-8-million-ceo-says-tariff-related-exposure-limited" target="_blank" rel="noreferrer noopener">AstraZeneca Q1 Earnings Rise, But China Drug Allegations May Lead To $8 Million Penalty</a></li>
</ul>
Photo: ShU studio/Shutterstock

Biotech

Large Cap

Health Care

General

Pfizer's Covid Windfall Shrinks, Expands Cost-Cutting Efforts

Keefe, Bruyette &amp; Woods analyst Ryan Krueger maintains Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) with a Market Perform and lowers the price target from $520 to $510.

Keefe, Bruyette & Woods Maintains Market Perform on Ameriprise Finl, Lowers Price Target to $510

WW International Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) shares are trading higher by 110% to 87 cents during Tuesday&#8217;s session after the company announced a <a href="https://www.benzinga.com/pressreleases/25/04/g45066438/weightwatchers-streamlines-member-access-to-zepbound-vials-with-lillydirect-pharmacy-provider">new partnership</a> with Eli Lilly's LillyDirect pharmacy provider, Gifthealth, to simplify access to the popular weight loss drug Zepbound for its clinic members.
What To Know: WeightWatchers says this integration allows eligible self-pay patients, without insurance coverage, to receive prescriptions for Zepbound in single-dose vial form directly through the WeightWatchers app, which now includes real-time tracking and a streamlined fulfillment process.
Per WeightWatchers, Zepbound usage has surged among WeightWatchers Clinic members, with prescriptions for the vial format more than doubling in recent months. 
WeightWatchers says, currently, 33% of the clinic's patients use Zepbound as part of their weight management plan. Executives from both WeightWatchers and Gifthealth emphasized the benefits of this integration in improving transparency, pricing and ease of access. 
WeightWatchers also says the company continues to combine medical treatments like GLP-1s with behavioral support. Their approach has yielded significant results—patients have achieved an average 21% weight loss over 12 months, outperforming GLP-1 use alone.
Read Also: <a href="https://www.benzinga.com/news/25/04/45069925/coca-cola-boasts-q1-eps-beat-as-revenue-jumps-in-europe-middle-east-and-africa">Coca-Cola Boasts Q1 EPS Beat As Revenue Jumps In Europe, Middle East And Africa</a>
<h2 class="wp-block-heading">How To Buy WW Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in WW International&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, WW has a 52-week high of $2.35 and a 52-week low of $0.12.

WeightWatchers Integrates With Eli Lilly To Expand Access To Zepbound, Stock Skyrockets 110%

Scotiabank analyst Divya Goyal maintains EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) with a Sector Outperform and lowers the price target from $250 to $200.

EPAM

Scotiabank Maintains Sector Outperform on EPAM Systems, Lowers Price Target to $200

Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) has outperformed the market over the past 5 years by 9.06% on an annualized basis producing an average annual return of 23.33%. Currently, Johnson Controls Intl has a market capitalization of $53.59 billion. 
Buying $1000 In JCI: If an investor had bought $1000 of JCI stock 5 years ago, it would be worth $2,921.39 today based on a price of $81.18 for JCI at the time of writing.
<h3>Johnson Controls Intl's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745940623_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Johnson Controls Intl Stock In The Last 5 Years

Scotiabank analyst Divya Goyal maintains Alithya Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALYA#TSX">ALYA</a>) with a Sector Perform and lowers the price target from C$2.8 to C$2.5.

TSX:ALYA

Scotiabank Maintains Sector Perform on Alithya Group, Lowers Price Target to C$2.5

WIIM

Smithfield Foods shares are trading higher following a Q1 EPS and revenue beat.

CNO Financial Group shares are trading lower after the company reported Q1 financial results.

UFPI

UFP Industries shares are trading lower after the company reported worse-than-expected Q1 financial results.

Crane shares are trading higher after the company reported better-than-expected Q1 financial results. Also, UBS upgraded the stock from Neutral to Buy and raised its price target from $157 to $190.

FELE

Franklin Electric shares are trading lower after the company reported Q1 financial results and missed its EPS and revenue estimates.

JP Morgan analyst Domingos Falavina maintains Vinci Partners Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) with a Overweight and lowers the price target from $15 to $13.5.

VINP

JP Morgan Maintains Overweight on Vinci Partners Inv, Lowers Price Target to $13.5

LifeMD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) shares are trading higher Tuesday after the company announced it will offer <a href="https://www.benzinga.com//node/45064487">access to Wegovy.</a>
What To Know: LifeMD said it will offer access to Wegovy through Novocare Pharmacy, allowing the company to provide the weight-loss drug at a lower self-pay price of $499 per month.
The company said this offering reflects the growing demand among cash-pay patients for convenient access to clinically backed FDA-approved obesity treatment options.
&#8220;By embedding direct access to Wegovy&nbsp;via NovoCare Pharmacy into our platform, we&#8217;re enhancing the patient experience, expanding access to a critical medication, and reinforcing LifeMD&#8217;s position as a leader in delivering comprehensive, technology-enabled obesity care,&#8221; said Justin Schreiber, Chairman and CEO of LifeMD.
Related Link: <a href="https://www.benzinga.com/trading-ideas/technicals/25/04/45067829/microsoft-q3-earnings-azure-may-rise-30-thats-not-where-ctos-are-aggressively-spending-analyst-warns">Microsoft Q3 Earnings: Azure May Rise 30% &#8211; That&#8217;s Not Where &#8216;CTOs Are Aggressively Spending&#8217; Analyst Warns</a>
LFMD Price Action: At the time of writing, LifeMD shares are trading 19.8% higher at $7.31, according to data from Benzinga Pro.
Image: via Shutterstock

LFMD

LifeMD Stock Pops As Company Expands Weight-Loss Offerings With Wegovy

Press Releases

Nvni Group Limited reports 2023 FY results: Net Revenue growth of 36%, Adjusted EBITDA up 142%

NVNI Group Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(2)

Nuvini Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

Nuvini Group Limited Reports Strong Growth in First Half 2024 Results

Nuvini Regains Compliance with Nasdaq Listing Rule 5250(c)(2)

Nvni Group Engages MZ Group to Lead Investor Relations and Shareholder Communications Program

Nvni Group to Participate in the 37th Annual ROTH Conference

AI Co's: ARBB, GEVI, CYCU, CBDW + More Driving Innovation Across Industries

Nuvini Group Announces Term Sheet for the Acquisition of B2B SaaS Platform Munddi

Comments

Nvni Group

Noticias

Últimas noticias sobre Nvni Group (NASDAQ:NVNI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL